Noble (2009) proposed that the immune system accumulates a nonspecific 'memory of danger': prior exposure to innate danger signals leaves memory CD8 T-cell pools hyper-responsive to later, antigen-unrelated inflammation, providing a mechanistic basis for phenomena behind the hygiene hypothesis. The review closed with five linked unresolved issues: the relative contribution of TNF-alpha, CD40L, and chemokines to this effect; whether CD8 memory T cells are its exclusive reservoir; the relative roles of structural tissue cells versus dendritic cells in sensing danger at barrier surfaces; the existence (and tissue dependence) of a hierarchy in which type I interferon signals dominate over GM-CSF/IL-1 or TSLP in eliciting Th1/CD8 rather than Th2 responses; and whether Th1/CD8-skewing vaccines can confer nonspecific protection against allergic disease. The subsequent literature on bystander activation, trained immunity, epithelial alarmins, and BCG trials leaves open: a quantitative mechanistic dissection of mediator contributions and reservoirs; the relative roles of structural tissue cells versus dendritic cells in danger sensing; the danger-signal-to-subset hierarchy; and whether vaccines skewing immunity toward CD8/Th1 responses confer nonspecific protection against allergic disease.

Background

Immunological memory is classically defined as the antigen-specific property of adaptive lymphocytes: T and B cells that have encountered their cognate antigen persist in elevated numbers and respond faster upon re-encounter. T cells carry a T-cell receptor (TCR) recognizing a specific peptide fragment; CD8 T cells (cytotoxic T cells) recognize fragments presented on MHC (major histocompatibility complex) class I molecules, while CD4 helper T cells differentiate into effector lineages such as Th1 (driving cell-mediated immunity, largely via interferon-gamma) and Th2 (driving allergic responses mediated by IgE, the antibody class that triggers allergy). A complementary axis of immune regulation concerns 'danger signals': molecular patterns associated with pathogens (PAMPs) or tissue injury (DAMPs), such as bacterial lipopolysaccharide or viral nucleic acids, which are sensed by innate receptors (e.g. Toll-like receptors) on dendritic cells — the antigen-presenting cells that instruct T-cell responses — and on structural tissue cells such as respiratory epithelium. Danger sensing determines the size, nature, and longevity of a response; antigens determine its specificity.

A key precedent showed that the two axes are not independent: Tough, Borrow, and Sprent (Science, 1996) demonstrated that viral infection and type I interferons (antiviral cytokines) induce TCR-independent ('bystander') proliferation specifically of memory-phenotype CD8 T cells in vivo. Building on this and related findings, Noble (Trends in Immunology, 2009) proposed a modified model of immune regulation in which recognition of danger has long-lasting effects on CD8 memory T-cell populations — enhancing early cytokine release and altering the nature of subsequent, antigen-unrelated responses — so that a nonspecific immunological 'memory of danger' accumulates during maturation of the immune system, potentiating cell-mediated immunity in dangerous environments. He suggested such a mechanism could underlie phenomena associated with the hygiene hypothesis (the epidemiological observation that low early-life microbial exposure associates with more allergic disease). Noble's own group had shown that an antigen-specific MHC class I-restricted (CD8-skewing) allergen peptide vaccine suppresses allergic airway inflammation and IgE in mice (Wells, Choy, Lloyd, and Noble, Mucosal Immunology, 2009), but the nonspecific version of the idea remained untested.

The mechanistic terminology of the open questions: TNF-alpha (tumor necrosis factor-alpha, an inflammatory cytokine produced during bystander responses with slower kinetics than early interferons), CD40L (CD40 ligand, a T-cell surface molecule engaging CD40 on antigen-presenting cells), and chemokines (small attractant cytokines) are candidate mediators whose individual contributions to the memory-of-danger effect had not been quantified. GM-CSF (granulocyte-macrophage colony-stimulating factor) and IL-1 (interleukin-1) versus TSLP (thymic stromal lymphopoietin, an epithelial cytokine skewing responses toward Th2) are candidate danger-linked instructive signals for T-cell subset selection, with type I interferons favoring Th1/CD8 responses. 'Trained immunity' designates the later-established capacity of innate cells (monocytes, macrophages, natural killer cells) to mount memory-like heightened responses after prior danger exposure via epigenetic reprogramming — a concept adjacent to, and partially overlapping with, the memory-of-danger proposal.

Problem Statement

Noble (2009) asked whether the immune system builds a nonspecific 'memory of danger' — a lasting, antigen-independent heightening of memory T-cell responsiveness caused by prior exposure to innate danger signals — and left open the mechanisms, scope, and exploitability of such memory as five linked issues sharing one objective: to determine mechanistically how danger experience is stored and expressed and whether it can be harnessed. The open problem comprises: (1) Mediators: establish the relative contribution of TNF-alpha (produced with slower kinetics), CD40L expression, and chemokine release to the memory-of-danger effect. (2) Reservoirs: determine whether CD8 memory T cells are the exclusive reservoir of memory of danger, including whether CD4 memory and B-cell memory also maintain heightened danger responsiveness, alongside the innate reservoirs (trained immunity) established after the review. (3) Tissue sensing: establish the relative roles of structural tissue cells versus dendritic cells in sensing danger and inducing bystander activation of memory cells, particularly at the respiratory epithelium in asthma initiation. (4) Signal hierarchy: determine whether type I interferon signals dominate over GM-CSF/IL-1 or TSLP in eliciting Th1/CD8 rather than Th2 responses, and whether that comparison is tissue-specific. (5) Translational test: determine whether vaccines inducing strong CD8 and Th1 responses confer nonspecific protection against allergic disease; post-2009 randomized trials have probed this question through BCG (bacillus Calmette-Guérin, a live tuberculosis vaccine), and it remains open. These five questions support one scientific objective — a mechanistic and quantitative account of how innate danger experience is stored, by which cells, through which signals, with what subset-selecting rules, and with what exploitable protective consequence. Each sub-question is independently resolvable, has its own completion criterion, and may stand alone as a partial contribution: (1) is resolved by a quantitative attribution of the effect among TNF-alpha, CD40L, and chemokines; (2) by an evidence-based determination of whether CD8 memory T cells are the exclusive reservoir and, if not, which other reservoirs qualify; (3) by a comparative assessment of the relative roles of structural tissue cells versus dendritic cells in danger sensing and bystander activation; (4) by a settled answer to the named danger-signal-to-subset comparison and whether it is tissue-specific; and (5) by an evidence-based determination of whether CD8/Th1-skewing vaccines confer nonspecific protection against allergic disease. A complete answer addresses all five as components of the one objective above, but the parts are judged separately: no part depends on another's resolution, and a defensible answer to a subset of them is a valid partial result rather than a resolution of the whole task.

References

  1. Noble A. Do we have memory of danger as well as antigen? Trends in Immunology 30(4):150-156 (2009). DOI 10.1016/j.it.2009.02.001, https://doi.org/10.1016/j.it.2009.02.001
  2. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272(5270):1947-1950 (1996). DOI 10.1126/science.272.5270.1947, https://doi.org/10.1126/science.272.5270.1947
  3. Wells JW, Choy K, Lloyd CM, Noble A. Suppression of allergic airway inflammation and IgE responses by a class I restricted allergen peptide vaccine. Mucosal Immunology 2(1):54-62 (2009). DOI 10.1038/mi.2008.69, https://doi.org/10.1038/mi.2008.69
  4. Cooper MA, Yokoyama WM. Memory-like responses of natural killer cells. Immunological Reviews 235(1):297-305 (2010). DOI 10.1111/j.0105-2896.2010.00891.x, https://doi.org/10.1111/j.0105-2896.2010.00891.x
  5. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host & Microbe 9(5):355-361 (2011). DOI 10.1016/j.chom.2011.04.006, https://doi.org/10.1016/j.chom.2011.04.006
  6. Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nature Reviews Immunology 20(6):375-388 (2020). DOI 10.1038/s41577-020-0285-6, https://doi.org/10.1038/s41577-020-0285-6
  7. Lee H, Jeong S, Shin EC. Significance of bystander T cell activation in microbial infection. Nature Immunology 23(1):13-22 (2022). DOI 10.1038/s41590-021-00985-3, https://doi.org/10.1038/s41590-021-00985-3
  8. Paprckova D, Salyova E, Michalik J, Stepanek O. Bystander activation in memory and antigen-inexperienced memory-like CD8 T cells. Current Opinion in Immunology 82:102299 (2023). DOI 10.1016/j.coi.2023.102299, https://doi.org/10.1016/j.coi.2023.102299
  9. Linehan MF, Nurmatov U, Frank TL, Niven RM, Baxter DN, Sheikh A. Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis. Journal of Allergy and Clinical Immunology 133(3):688-695 (2014). DOI 10.1016/j.jaci.2013.08.007, https://doi.org/10.1016/j.jaci.2013.08.007
  10. Thøstesen LM, Kjærgaard J, Pihl GT, Birk NM, Nissen TN, Aaby P, Jensen AKG, Olesen AW, Stensballe LG, Jeppesen DL, Benn CS, Kofoed P-E. Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial. Allergy 73(2):498-504 (2018). DOI 10.1111/all.13314, https://doi.org/10.1111/all.13314
  11. Pittet LF, Thøstesen LM, Aaby P, Kofoed PE, Curtis N, Benn CS. Neonatal Bacillus Calmette-Guérin Vaccination to Prevent Early-Life Eczema: A Systematic Review and Meta-analysis. Dermatitis 33(6S):S3-S16 (2022). DOI 10.1097/DER.0000000000000945, https://doi.org/10.1097/DER.0000000000000945
  12. Xie C, Wei Y, Su C, Yalikun M, Chu Y, Yu H, Jin M, Xu W, Lin J, Dong J. Mechanisms and therapeutic strategies of asthma: from bench to bedside. Signal Transduction and Targeted Therapy 11(1):317 (2026). DOI 10.1038/s41392-026-02853-8, https://doi.org/10.1038/s41392-026-02853-8